Patents by Inventor James R. Empfield

James R. Empfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metabotropic glutamate-receptor-potentiating isoindolones
    Patent number: 8153638
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators
    Publication number: 20110166155
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: January 6, 2011
    Publication date: July 7, 2011
    Inventors: Bradford VAN WAGENEN, Radhakrishnan UKKIRAMAPANDIAN, Joshua CLAYTON, Ian EGLE, James R. EMPFIELD, Methvin ISAAC, Fupeng MA, Abdelmalik SLASSI, Gary STEELMAN, Rebecca URBANEK, Sally WALSH
  • Metabotropic Glutamate-Receptor-Potentiating Isoindolones
    Publication number: 20100317674
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: August 23, 2010
    Publication date: December 16, 2010
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Metabotropic glutamate-receptor-potentiating isoindolones
    Patent number: 7807706
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: October 5, 2010
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Substituted Amino-Compounds and Uses Thereof
    Publication number: 20090221579
    Abstract: This invention relates to novel compounds having the structural formula Ia or formula Ib: Ia Ib and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of A? related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: October 14, 2005
    Publication date: September 3, 2009
    Inventors: Jeffrey Scott Albert, Don Andisik, James Arnold, Dean Brown, Owen Callaghan, James Campbell, Robin Arthur Ellis Carr, Gianni Chessari, Miles Stuart Congreve, Phil Edwards, James R. Empfield, Martyn Frederickson, Gerard M. Koether, Jennifer Krumrine, Russ Mauger, Christopher William Murray, Sahil Patel, Mark Sylvester, Scott Throner
  • Metabotropic Glutamate Receptor-Potentiating Isoindolones
    Publication number: 20090149505
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description, processes for the preparing such compounds, new intermediates employed in their preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: February 6, 2007
    Publication date: June 11, 2009
    Applicant: AstraZeneca AB
    Inventors: James R. Empfield, James J. Folmer, James R. Arnold, Joshua Clayton, Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma
  • SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
    Publication number: 20090111830
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: February 15, 2006
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Substituted Amino-Pyrimidones and Uses Thereof
    Publication number: 20090062282
    Abstract: This invention relates to novel compounds having the structural formula Ia or formula Ib below: (Ia, Ib), and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of A? related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: October 14, 2005
    Publication date: March 5, 2009
    Applicant: AstraZeneca AB
    Inventors: Jeffrey Scott Albert, Don Andisik, James Arnold, Dean Brown, Owen Callaghan, James Campbell, Robin Arthur Ellis Carr, Gianni Chessari, Miles Stuart Congreve, Phil Edwards, James R. Empfield, Martyn Frederickson, Gerard M. Koether, Jennifer Krumrine, Russ Mauger, Christopher William Murray, Sahil Patel, Mark Sylvester, Scott Throner
  • Therapeutic Agents
    Publication number: 20080306087
    Abstract: The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 3, 2006
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: James R. Empfield, Michael Laplante, Megan Murphy King, Thomas R. Simpson, Maxime C. Tremblay, James M. Woods, Jingbo Yan
  • Metabotropic Glutamate-Receptor-Potentiating Isoindolones
    Publication number: 20080227794
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: February 15, 2006
    Publication date: September 18, 2008
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Therapeutic Agents
    Publication number: 20080214570
    Abstract: The present invention relates to compounds of formula I and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 3, 2006
    Publication date: September 4, 2008
    Applicant: ASTRAZENECA AB
    Inventors: James R. Empfield, Michael Laplante, Megan Murphy King
  • 4-substituted imidazoles
    Patent number: 7384954
    Abstract: Compounds of formula I: wherein A and R1 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: June 10, 2008
    Assignee: AstraZeneca AB
    Inventors: James R. Empfield, Eifion Phillips, Scott Throner
  • Amidine derivatives which are inhibitors of nitric oxide synthase
    Publication number: 20020137750
    Abstract: There are provided novel compounds of formula (I) 1
    Type: Application
    Filed: February 27, 2001
    Publication date: September 26, 2002
    Inventors: D.W. Chen Deborah, James R. Empfield, James E. Macdonald, Kenneth C. Mattes, Robert Murray, Eifion Phillips, Hans Schmitthenner
  • Aminosulfonylphenyl compounds for treating urinary incontinence
    Patent number: 5510386
    Abstract: Compounds of formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A-B have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinery incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: April 23, 1996
    Assignee: Zeneca Limited
    Inventors: James R. Empfield, Daniel R. Mayhugh, Keith Russell
  • Certain N(4-benzoyl-2-phenyl)-3- trifluoro-2-hydroxy-propanamide derivatives
    Patent number: 5482969
    Abstract: Compounds of formula I: ##STR1## wherein, ring C, A-B, R.sup.1, n, R.sup.2, and R.sup.3 have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinary incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: January 9, 1996
    Assignee: Zeneca Limited
    Inventors: James R. Empfield, Cyrus J. Ohnmacht, Keith Russell, Diane A. Trainor, Paul J. Warwick, Jr.
  • Therapeutic alcohols
    Patent number: 5411973
    Abstract: Compounds of formula I ##STR1## wherein X, A, B, R.sup.1 and R.sup.2 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable ester thereof, processes for preparing the compounds and pharmaceutical compositions comprising them. The compounds are useful as potassium channel openers and as therapeutic agents in the treatment of urinary incontinence.
    Type: Grant
    Filed: May 18, 1993
    Date of Patent: May 2, 1995
    Assignee: Zeneca Limited
    Inventors: Keith Russell, James R. Empfield, Cyrus J. Ohnmacht, Keith H. Gibson